INDIA’S biggest bank, the State Bank of India (SBI), has reported an increase of 80 per cent in standalone net profit at Rs 64.51 billion (£624.67 million) for the fourth quarter ended March 2021.
Increase in net profit was helped by decline in bad loans and higher interest income.
The bank registered a profit of Rs 35.80 billion (£346.68 million) during January-March period of 2019-20.
Net NPA or bad loans came down to 1.50 per cent as on March 31, 2021 from 2.23 per cent in the year-ago period, it said in a regulatory filing on Friday (21).
The lender reportedly received nearly Rs 40 billion (£387.32 million) as part of dues owed by bankrupt steelmaker Bhushan Power and Steel.
In March, JSW Steel acquired Bhushan Power and Steel and implemented the resolution plan for the company where SBI was the lead banker.
Total income of the lender during the March quarter of the last financial year rose to Rs 813.27 billion (£787.9 million), from Rs 760.27 billion (£736.77 million) in the same period of 2019-20.
On a consolidated basis, the bank reported a 60 per cent increase in net profit at Rs 72.70 billion (£70.43 million) compared to Rs 45.57 billion (£44.15 million) in the fourth quarter of the previous fiscal.
For the entire financial year 2020-21, the bank reported a 41 per cent jump in standalone profit at Rs 201.10 billion (£194.83 million), from Rs 144.88 billion (£140.42 million) in the previous financial year.
The central board of the bank has also declared a dividend of Rs. 4.00 (£0.04) per equity share for the financial year ended 31st March, 2021. This is the first payout by SBI since May 2017, when it had rewarded shareholders with Rs. 2.6 (£0.03) per share.
The bank has fixed June 18, 2021 as the date of payment of dividend.
Shares of SBI closed at Rs 401.10 per unit, up 4.3 per cent on the Bombay Stock Exchange (BSE) today.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.